Quelimmune Shows Promise in Pediatric Acute Kidney Injury
SeaStar Medical announced positive preliminary results from its SAVE Surveillance Registry for its QUELIMMUNE therapy in critically ill pediatric...
eClinical Tech News
Obefazimod Shows Positive Phase 3 Results in Ulcerative Colitis Trials
Abivax reported positive Phase 3 results for obefazimod, a first-in-class oral miR-124 enhancer, in two induction trials for moderate...
Bio-Hermes Study: Transforming Alzheimer’s Research
IXICO, a neuroscience imaging and biomarker analytics company, has joined the Bio-Hermes-002 study, a collaborative effort aimed at improving...
First Patient Dosed in Tamarind Trial for MDD
HMNC Brain Health and Spruce Biosciences have dosed the first patient in the Phase 2 TAMARIND clinical trial. This...
Study: Perimenopause Most Misunderstood Health Transition
Bonafide Health’s fifth annual State of Menopause Study reveals that women aged 40-49 are significantly impacted by perimenopause, experiencing...
LifeVantage Announces Expanded Human Clinical Study, 200% GLP-1 Surge
LifeVantage Corporation announced positive results from a combined analysis of two clinical trials on its MindBody GLP-1 System, a...
Efzofitimod Phase 3 Study Completes Last Patient Visit
aTyr Pharma completed the final patient visit in its Phase 3 EFZO-FIT™ study of efzofitimod for pulmonary sarcoidosis, anticipating...
CytoMed Therapeutics Achieves Angelica Trial Milestone
CytoMed Therapeutics, a Singapore-based biopharmaceutical company, announced the successful completion of dose level 1 in its first-in-human Phase I...
Optima II Trial Shows Long-Term Durability of Zusduri in Bladder Cancer
A five-year long-term extension study of the Phase 2b OPTIMA II trial, published in Clinical Genitourinary Cancer, demonstrated durable...
Arrivent’s Pivotal Phase 3 Furvent Data for Firmonertinib Projected Early 2026
ArriVent BioPharma anticipates topline data from its global Phase 3 FURVENT trial in early 2026. The trial is evaluating...